PMID- 37342361
OWN - NLM
STAT- MEDLINE
DCOM- 20230623
LR  - 20230701
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 29
DP  - 2023
TI  - Cytokine-induced killer cell treatment is superior to chemotherapy alone in 
      esophageal cancer.
PG  - 1610710
LID - 10.3389/pore.2023.1610710 [doi]
LID - 1610710
AB  - Background: The therapeutic efficacy of cytokine-induced killer (CIK) cells 
      versus dendritic cells (DC) co-cultured with CIK cells (DC-CIK) in treating 
      esophageal cancer (EC) remains unclear due to the absence of a direct comparison 
      of these two regimens. This study evaluated the comparative efficacy and safety 
      of CIK cells versus DC-CIK using network meta-analysis in treating EC. Material 
      and methods: We identified eligible studies from previous meta-analyses, then 
      conducted an updated search to retrieve additional trials between February 2020 
      and July 2021. The primary outcomes included overall survival (OS), objective 
      response rate (ORR), and disease control rate (DCR), and the secondary outcomes 
      included quality of life improved rate (QLIR) and adverse events (AEs). A network 
      meta-analysis of 12 studies was conducted using ADDIS software. Results: Twelve 
      studies were identified, including six comparing CIK or DC-CIK plus chemotherapy 
      (CT) with CT alone. Immunotherapy plus CT significantly improved overall survival 
      (OS) (odds ratio [OR] 4.10, 95% confidence interval [CI] 1.23-13.69), objective 
      response rate (ORR) (OR 2.72, 95% CI 1.79-4.11), disease control rate (DCR) (OR 
      3.45, 95% CI 2.32-5.14), and quality of life improvement rate (QLIR) (OR 3.54, 
      95% CI 2.31-5.41). DC-CIK+CT decreased the risk of leukopenia compared with CT 
      alone. However, no statistical difference was detected between CIK-CT and 
      DC-CIK+CT. Conclusion: Based on the available evidence, we concluded that CIK 
      cell treatment is superior to CT alone, but CIK-CT and DC-CIK+CT may be 
      comparable in treating EC. However, comparing CIK-CT and DC-CIK+CT is only based 
      on indirect evidence, so it is undoubtedly necessary to conduct studies to 
      compare CIK-CT with DC-CIK+CT in EC patients directly.
CI  - Copyright (c) 2023 Sun, Sun, Miniderima and Wang.
FAU - Sun, Jiayang
AU  - Sun J
AD  - Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical 
      University, Hohhot, Inner Mongolia, China.
FAU - Sun, Yushu
AU  - Sun Y
AD  - Department of Oncology, Inner Mongolia Cancer Hospital and Affiliated People's 
      Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
FAU - Miniderima
AU  - Miniderima
AD  - Department of Oncology, Inner Mongolia Cancer Hospital and Affiliated People's 
      Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
FAU - Wang, Xiumei
AU  - Wang X
AD  - Department of Oncology, Inner Mongolia Cancer Hospital and Affiliated People's 
      Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230605
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
SB  - IM
MH  - Humans
MH  - *Cytokine-Induced Killer Cells
MH  - Quality of Life
MH  - Dendritic Cells
MH  - Immunotherapy, Adoptive
MH  - *Lung Neoplasms
MH  - *Esophageal Neoplasms/therapy
PMC - PMC10277884
OTO - NOTNLM
OT  - cytokine-induced killer cells
OT  - dendritic cells
OT  - esophageal cancer
OT  - immunotherapy
OT  - network meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/21 13:04
MHDA- 2023/06/23 06:42
PMCR- 2023/06/05
CRDT- 2023/06/21 12:00
PHST- 2022/07/15 00:00 [received]
PHST- 2023/05/18 00:00 [accepted]
PHST- 2023/06/23 06:42 [medline]
PHST- 2023/06/21 13:04 [pubmed]
PHST- 2023/06/21 12:00 [entrez]
PHST- 2023/06/05 00:00 [pmc-release]
AID - 1610710 [pii]
AID - 10.3389/pore.2023.1610710 [doi]
PST - epublish
SO  - Pathol Oncol Res. 2023 Jun 5;29:1610710. doi: 10.3389/pore.2023.1610710. 
      eCollection 2023.